NMIBC 2026 – IBRX, CGON, ENGN: bladder-sparing race after BCG failure
High-risk non-muscle-invasive bladder cancer after failure of BCG has become one of the hottest oncology niches of 2025–2026. ImmunityBio with ANKTIVA is already on the market, while CG Oncology and enGene are coming fast with late-stage programs. This report compares mechanisms, clinical data, timelines and sentiment, so traders can look beyond the single name that is dominating the headlines in these weeks.
IBRX
ImmunityBio
ANKTIVA in BCG-unresponsive NMIBC
Source: Finviz
CGON
CG Oncology
Cretostimogene in BCG-unresponsive / intermediate-risk NMIBC
Source: Finviz
ENGN
enGene
Detalimogene (EG-70) gene therapy platform
Source: Finviz
1. Why this comparative NMIBC report
Over the last months ImmunityBio has moved from being just another late-stage oncology name to a real retail phenomenon. ANKTIVA is now approved for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) in the United States and has just received an accelerated approval in Saudi Arabia as well, while preliminary revenues are ramping quickly. In parallel, CG Oncology and enGene are trying to carve out their own space in the same post-BCG niche with very competitive data and clear regulatory paths.
Instead of looking only at IBRX in isolation, this report is built as a deep comparative research on three companies playing in the same clinical segment: ImmunityBio (IBRX), CG Oncology (CGON) and enGene (ENGN). The goal is not to crown a winner, but to give traders a broader menu of ideas inside the same story: bladder-sparing options for patients who either fail BCG or cannot undergo radical cystectomy.
All data and timelines here are based on official sources: company press releases, peer-reviewed abstracts and major oncology/urology media. Links are provided throughout, so every number can be cross-checked directly.
2. Clinical context – what “BCG-unresponsive” really means
High-risk NMIBC is a recurrent, tricky disease. Patients typically start with intravesical therapy based on BCG. A substantial fraction, however, will either not respond at all or will relapse after an apparently adequate BCG course. These patients are labelled as BCG-unresponsive high-risk NMIBC, particularly when carcinoma in situ (CIS) is present, with or without papillary lesions. Historically the gold standard in this setting has been radical cystectomy with urinary diversion, a morbid and life-changing procedure that many patients refuse or are medically unfit to receive.
Before the recent wave of approvals and late-stage programs, the non-surgical field was dominated by systemic pembrolizumab (KEYTRUDA), with a complete response rate around forty percent at three months in CIS patients and a median duration of response in the range of sixteen months; and by intravesical gene therapy with nadofaragene firadenovec (Adstiladrin), which has shown around fifty-plus percent complete response rates but has been limited by manufacturing and supply issues in real life.
The unmet need is therefore clear. Patients, urologists and payors are searching for therapies that can preserve the bladder, provide durable control of disease and at the same time remain logistically feasible for everyday practice. This is exactly the playing field where ANKTIVA, cretostimogene and detalimogene are trying to position themselves.
3. ImmunityBio (IBRX) – ANKTIVA and the first wave
3.1 Mechanism and positioning
ANKTIVA (nogapendekin alfa inbakicept-pmln, also known as N-803) is an IL-15 receptor superagonist designed to expand and activate natural killer cells and CD8 T cells with a more favourable safety profile than classic IL-2. In NMIBC it is given intravesically in combination with BCG, with the idea of reinforcing and prolonging the immune response triggered by BCG itself.
The pivotal data come from the QUILT-3.032 program, a single-arm, multicentre study in BCG-unresponsive high-risk NMIBC patients with CIS, with or without papillary disease. According to ImmunityBio and subsequent independent summaries, ANKTIVA plus BCG achieved a 71% complete response rate in this population, with durable responses extending beyond four years in some cases. The company has reported cystectomy-free survival of roughly 84% at thirty-six months and disease-specific overall survival close to 99%. These figures have been repeatedly confirmed in press releases and congress presentations. Key sources include the company communication from November 2024 and a follow-up release in April 2025: ImmunityBio – QUILT-3.032 71% CR, 36-month bladder preservation data, and the EMA acceptance press release.
3.2 Regulatory status and global footprint
On the regulatory side, ANKTIVA has already crossed several milestones. It is approved by the FDA in the United States for adult patients with high-risk BCG-unresponsive NMIBC CIS with or without papillary disease who are ineligible for or decline cystectomy. In the United Kingdom, the MHRA granted approval in July 2025 for the same indication, cementing ANKTIVA as a new bladder-sparing standard after BCG failure in that market. More recently, the Saudi Food and Drug Authority has granted an accelerated approval for the same NMIBC indication, on top of a separate approval in non-small cell lung cancer in combination with an immune checkpoint inhibitor. The official Saudi NMIBC announcement can be found on ImmunityBio’s website: Saudi FDA approval – company release and in the corresponding investor-relations version: IR news release.
In the European Union, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion in late 2025 recommending a conditional marketing authorisation for ANKTIVA plus BCG in BCG-unresponsive high-risk NMIBC with CIS. ImmunityBio, in its most recent press releases, refers to this as a “conditional approval in the EU”, while the final formal decision by the European Commission is being completed. Practically, this places the effective EU market window for ANKTIVA in the 2026–2027 timeframe, subject to national reimbursement and implementation.
3.3 Pipeline beyond BCG-unresponsive
ImmunityBio is also running QUILT-2.005, a large study exploring the combination of ANKTIVA and BCG in earlier-line NMIBC settings, including BCG-naive patients. The company has disclosed that enrolment is advanced and that interim data support continuation of the program. If positive, these data could move ANKTIVA upstream, expanding the addressable population well beyond the relatively narrow BCG-unresponsive segment. Timelines here are longer and more uncertain, but the direction of travel is clear: from rescue therapy towards first-line bladder-sparing strategy.
3.4 Revenues, cash and risk profile
From a financial perspective ImmunityBio is the only name in this comparative report already generating meaningful product revenue. Preliminary 2025 numbers indicate around 113 million dollars of net product revenue, up roughly seven-fold year-on-year, almost entirely driven by ANKTIVA in NMIBC. The company has communicated cash and equivalents in the range of 240 million dollars at year-end 2025, but remains loss-making with substantial research, development and commercial expenses.
For traders this translates into a typical late-stage biotech profile: on one hand real sales, growing adoption and multiple geographic catalysts; on the other, a capital-intensive model that may still require future equity raises if the revenue curve does not steepen quickly enough.
4. CG Oncology (CGON) – oncolytic virus with late-stage ambitions
4.1 Cretostimogene grenadenorepvec in BCG-unresponsive NMIBC
CG Oncology’s main asset, cretostimogene grenadenorepvec (CG0070), is an intravesical oncolytic adenovirus engineered to replicate preferentially in tumour cells and express GM-CSF locally, enhancing antigen presentation and anti-tumour immunity. The pivotal study in high-risk BCG-unresponsive NMIBC is the BOND-003 phase 3 trial.
Topline data from BOND-003 show an overall complete response rate around 74.5% in CIS patients, with twelve-month outcomes that have attracted significant attention: more than ninety-seven percent of treated patients remain free from progression to muscle-invasive disease at one year and roughly ninety percent avoid radical cystectomy over the same period. Safety is reported as favourable, with no serious treatment-related grade 3 or higher events in the main analyses. The core numbers are summarised in CG Oncology’s news release “New cretostimogene data highlight its potential” and in independent urology reports such as Urology Times on BOND-003.
4.2 PIVOT-006 and the intermediate-risk space
Cretostimogene is not limited to the classic high-risk CIS population. CG Oncology is also running PIVOT-006, a phase 3 study in intermediate-risk NMIBC, where no modern innovative intravesical standard of care is firmly established. The company has indicated that PIVOT-006 is well underway and that top-line data are expected in the first half of 2026. If positive, this study could open a much broader commercial window, positioning cretostimogene as a bladder-sparing option earlier in the disease course. Programme details are outlined in the company’s late-2025 update and in clinical trial listings such as NCT04452591.
4.3 Regulatory path and cash position
CG Oncology has initiated a rolling Biologics License Application for cretostimogene in high-risk BCG-unresponsive NMIBC. Completion of the file is guided for 2026, with a formal PDUFA date to be set once the BLA is accepted in full. While the exact FDA decision window will only be clear at that point, a practical working assumption for traders is an approval horizon in late 2026 or 2027, subject of course to the agency’s review.
Financially the company is well funded for a pre-revenue biotech. Recent quarterly reports describe cash, equivalents and marketable securities in the high hundreds of millions of dollars, reflecting sizeable equity raises carried out in anticipation of commercialisation. The flip side is the absence of current product revenue: execution risk here is less about financing and more about how effectively CG Oncology can convert promising data into physician adoption once a label is granted.
5. enGene (ENGN) – non-viral gene therapy with FDA support
5.1 Detalimogene voraplasmid and the DDX platform
enGene’s candidate, detalimogene voraplasmid (EG-70), is built on the company’s proprietary DDX platform, a non-viral intravesical gene delivery system. Instead of using an adenovirus, detalimogene relies on a chemically derivatised chitosan carrier to deliver plasmid DNA encoding immunostimulatory payloads directly to the urothelial surface. The aim is to capture some of the immune-activating advantages of gene therapy while simplifying manufacturing and potentially improving safety and logistics.
5.2 LEGEND pivotal cohort – efficacy and safety
The main efficacy evidence comes from the LEGEND study, a multi-cohort phase 2 trial in high-risk NMIBC, with a pivotal cohort specifically focused on BCG-unresponsive CIS with or without papillary disease. According to the November 2025 press release titled “Detalimogene demonstrates improved complete response rate of 62% at 6 months”, and subsequent conference summaries, the post-amendment pivotal cohort shows:
an “any time” complete response rate of about sixty-three percent; a complete response rate of roughly fifty-six percent at three months; and, crucially, an improved six-month complete response rate of around sixty-two percent among evaluable patients. All five patients who had reached the nine-month visit at the time of that update remained in response. Treatment-related adverse events are reported in roughly forty-two percent of patients, with very low rates of dose interruption and discontinuation, suggesting a favourable tolerability profile.
5.3 Additional cohorts and broader positioning
LEGEND also includes cohorts in BCG-naive high-risk patients, in those who received insufficient BCG due to supply or toxicity issues, and in papillary-only disease. This reflects a deliberate strategy to position detalimogene not only as a rescue therapy but as a flexible intravesical platform across the entire high-risk NMIBC continuum. FDA has granted RMAT designation, Fast Track status and inclusion in the CMC Development and Readiness Pilot (CDRP) for EG-70, signalling regulatory interest in seeing the program advance efficiently.
5.4 Timelines and financial runway
Based on the company’s business update and the December 2025 financials (enGene full year 2025 results; BusinessWire enrolment milestone), enGene has completed enrolment of the pivotal cohort and plans to provide a more mature twelve-month data cut in the second half of 2026. The company guides for a BLA submission also in the second half of 2026, which implies a potential approval window around 2027 if the review process proceeds smoothly.
Cash and equivalents are described as sufficient to fund operations into the second half of 2028, giving the company a relatively long runway through the key regulatory milestones without structurally relying on new equity in the immediate future.
6. Side-by-side comparison – mechanisms, data, timelines
The three companies are attacking the same clinical space from different technological angles. All therapies are intravesical, designed to act locally in the bladder, but the way they trigger and shape the immune response is distinct. At a very high level: ANKTIVA is an IL-15 superagonist added on top of BCG; cretostimogene is an oncolytic virus that lyses tumour cells and secretes GM-CSF; detalimogene is a non-viral gene therapy delivering plasmids via a chitosan-based carrier.
| ImmunityBio (IBRX) | CG Oncology (CGON) | enGene (ENGN) | |
|---|---|---|---|
| Core asset | ANKTIVA (nogapendekin alfa inbakicept-pmln), IL-15 receptor superagonist | Cretostimogene grenadenorepvec (CG0070), oncolytic adenovirus expressing GM-CSF | Detalimogene voraplasmid (EG-70), non-viral intravesical gene therapy on DDX platform |
| Route and setting | Intravesical, in combination with BCG, high-risk BCG-unresponsive NMIBC with CIS ± papillary | Intravesical monotherapy (with combination programmes elsewhere); high-risk BCG-unresponsive NMIBC in BOND-003; intermediate-risk NMIBC in PIVOT-006 | Intravesical monotherapy; high-risk BCG-unresponsive NMIBC with CIS ± papillary in pivotal LEGEND cohort; additional cohorts in BCG-naive and papillary-only disease |
| Key efficacy read-outs in BCG-unresponsive CIS ± papillary | QUILT-3.032: around 71% complete response in CIS population, with long-term bladder preservation (cystectomy-free survival roughly 84% at 36 months; disease-specific OS close to 99%). Data consolidated across ImmunityBio releases and urology summaries. | BOND-003: about 74.5% complete response at any time in high-risk BCG-unresponsive CIS population, with approximately 97% of patients free from progression to muscle-invasive disease at 12 months and around 90% avoiding cystectomy at the same time point. | LEGEND (post-amendment pivotal cohort): around 63% “any time” complete response, about 56% at three months and roughly 62% at six months among evaluable patients; all five patients with nine-month data in the November 2025 update remained in response. |
| Safety snapshot | ANKTIVA plus BCG shows a tolerability profile dominated by local genitourinary events and low rates of high-grade systemic toxicity. Grade 3 treatment-related events appear uncommon and grade 4–5 events have not been prominent in reported datasets. | Cretostimogene has been described as well tolerated, with no grade 3 or higher treatment-related adverse events in main analyses, and a safety profile broadly aligned with intravesical viral therapy expectations. | Detalimogene demonstrates treatment-related adverse events in roughly forty-two percent of patients, but with very low incidence of dose interruptions and discontinuations, hinting at a manageable and locally driven toxicity profile. |
| Regulatory status in NMIBC | Approved in the United States for BCG-unresponsive high-risk NMIBC with CIS ± papillary; approved by the MHRA in the United Kingdom for the same indication; accelerated approval in Saudi Arabia; positive CHMP opinion recommending a conditional authorisation in the European Union, with final Commission decision pending. | No product approvals yet. Cretostimogene has Fast Track and Breakthrough Therapy designations for high-risk BCG-unresponsive NMIBC. A rolling BLA is underway, with completion guided for 2026. | No approvals yet. Detalimogene has RMAT designation, Fast Track, and inclusion in the FDA CDRP programme. BLA submission is planned for the second half of 2026. |
| Key 2026–2027 catalysts | Commercial uptake and quarterly ANKTIVA revenue trajectory; potential European approval and launch; additional updates from QUILT-2.005 and other expansion studies that could move the drug earlier in the NMIBC pathway. | Completion and acceptance of the BLA for high-risk BCG-unresponsive NMIBC (2026) with subsequent PDUFA; top-line PIVOT-006 data in intermediate-risk NMIBC expected in the first half of 2026. | Twelve-month LEGEND pivotal data update scheduled for the second half of 2026; BLA filing also guided for the second half of 2026, implying a potential approval window around 2027. |
7. Catalyst map for traders – how the calendar really looks
From a trading perspective the value of this cluster of names is less about a single binary event and more about a sequence of overlapping catalysts. ImmunityBio already has a label and is in the “execution and expansion” phase, while CG Oncology and enGene are in the classic “late-stage pre-approval” corridor where perception can shift quickly as new data and regulatory updates come in.
For IBRX, the near-term focus is on quarterly numbers and on the international roll-out of ANKTIVA. Saudi approvals and a possible positive EMA decision are important, but the market will probably look closely at real-world adoption curves and at any signals from QUILT-2.005 regarding movement into earlier-line disease. A strong and sustained increase in ANKTIVA revenue could compress the risk premium that still surrounds the stock.
For CGON, 2026 is primarily about two things: the mechanical completion and acceptance of the BLA for high-risk BCG-unresponsive NMIBC, and the read-out of PIVOT-006 in intermediate-risk disease. A clean dataset in PIVOT-006 would not only validate cretostimogene in a broader population, but also strengthen the company’s positioning when competing for urologist mindshare against both ANKTIVA and future entrants.
For ENGN, the line of sight is slightly longer but already well mapped: more mature twelve-month data from LEGEND in the second half of 2026 and the BLA submission in the same time frame. The FDA signalling through RMAT, Fast Track and CDRP inclusion is an additional lever that traders should keep in mind: it does not guarantee approval, but it does mean that the agency is actively engaged on both the clinical and manufacturing fronts.
8. Sentiment and retail chatter – what people are actually saying
The comments and trends summarised in this section come from public forums such as Reddit, Stocktwits and similar platforms. They reflect the opinions of non-professional traders and investors and should never be treated as investment advice or as a reliable source of factual information. They are useful to understand mood and positioning, not to replace fundamental analysis.
8.1 IBRX – between real revenues and squeeze narrative
Among the three names, IBRX is by far the most visible in retail communities. The combination of an approved oncology drug, rapidly increasing sales, a relatively low absolute share price and a sizeable short interest has created the perfect environment for short-squeeze and gamma-squeeze stories. Threads on dedicated ImmunityBio sub-communities and on more general penny-stock and short-squeeze forums repeatedly highlight estimates of high short interest and limited effective free float, with some users projecting extreme long-term market-capitalisation scenarios based on optimistic adoption and indication-expansion assumptions.
At the same time, more data-driven posters focus on the genuine progress: the seven-fold year-on-year increase in ANKTIVA revenue, the Saudi approvals in both bladder and lung cancer, and the possibility of European entry. The result is a hybrid narrative where solid fundamental achievements coexist with speculative price targets and where short-term trading flows can be as important as the underlying story in driving volatility.
8.2 CGON – strong respect, modest hype
CGON generates much less forum noise than IBRX, but the tone is often more disciplined. After the release of BOND-003 data and subsequent rallies, comments on trading boards and stock-focused channels tend to oscillate between admiration for the clinical results and caution on valuation after a strong run. External media pieces have framed CG Oncology as a serious contender in the NMIBC space, sometimes comparing cretostimogene to Johnson & Johnson’s TAR-200 in terms of durability of response.
For a trader this difference in tone matters: the presence of a strong underlying data story without an overwhelming squeeze narrative can sometimes translate into cleaner technical setups and into a market that reacts more directly to new fundamental information, rather than to positioning imbalances.
8.3 ENGN – small but vocal communities
ENGN sits somewhere in the middle. The stock has a smaller community, but spikes in borrow fees and tight share availability have occasionally fuelled discussions about potential short-squeeze setups. Threads on day-trading forums and on Stocktwits sometimes highlight very high reported borrow rates and low availability of shares to short, especially around company updates.
Overall, the sentiment around enGene is a mix of appreciation for the FDA designations and for the clean safety profile of detalimogene, combined with the usual binary-event anxiety that accompanies any pre-revenue biotech heading towards pivotal data and a first BLA.
9. My tale – why put these three names together
In preparing this report I deliberately decided not to stop at a single ticker. The idea was to use ImmunityBio’s current momentum as a starting point and then run a deep comparative research on other companies working in the same post-BCG bladder-sparing niche. The goal is not to promote one stock over another, but to offer traders a small ecosystem of names that share the same clinical territory, similar regulatory paths and overlapping timelines. Instead of chasing only the name that makes the most noise on social media in a given week, this cross-section allows readers to compare mechanisms of action, trial designs, response rates, durability and regulatory guidance across several approaches to the same problem. From there, everyone can decide how much risk to take, which stories to follow more closely and whether to focus on run-up phases or on longer-term execution.
10. Legal notes and risk reminder
This report is for educational and informational purposes only. It is not, and must not be interpreted as, an offer, invitation, solicitation or recommendation to buy or sell any financial instrument or to undertake any investment strategy. The companies and products mentioned are cited as case studies in the context of high-risk non-muscle-invasive bladder cancer and not as investment opportunities. Any decision to trade or invest should be based on an independent assessment of the investor’s objectives, risk tolerance and financial situation, possibly with the support of a qualified adviser.
The information is based on public sources believed to be reliable (including regulatory documents, company press releases and presentations at recognised scientific meetings), but it may contain inaccuracies or become outdated over time. All clinical and financial data should be checked directly on primary sources such as company investor-relations pages, official press releases and regulatory agency documents before being used in any decision process. Past performance of any stock or strategy is not indicative of future results.
Some tools or platforms mentioned in this report, such as Finviz, may be accessible through affiliate links on Merlintrader trading Blog. Where this is the case, any potential commission does not change the cost or conditions for the reader and does not influence the qualitative assessment of the products discussed. Full legal information, including the general disclaimer and the privacy and terms of use policies, is available here: Disclaimer – Condizioni d’uso e privacy.
Biotech Catalyst Calendar
If you want to follow not only these three names but the broader landscape of FDA decisions, clinical read-outs and key events in biotech, you can always refer to the dedicated Biotech Catalyst Calendar maintained on Merlintrader trading Blog.
It is updated on a regular basis and offers a structured view of upcoming binary events, run-up windows and relevant conferences.
More information here: Biotech Catalyst Calendar.